Thalidomide for inflammatory bowel disease: Systematic review

Medicine (United States)

Volumn 95, Issue 30, 2016, Pages

  Bramuzzo, Matteo ^a   Ventura, Alessandro ^a,b   Martelossi, Stefano ^a   Lazzerini, Marzia ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Crohn disease; inflammatory bowel disease; systematic review; thalidomide; ulcerative colitis

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; STEROID; THALIDOMIDE;

ANXIETY DISORDER; BIOLOGICAL THERAPY; COLON FISTULA; CONSTIPATION; CROHN DISEASE; DERMATITIS; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL THERAPY; EYE DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFARCTION; INFLAMMATORY BOWEL DISEASE; MOOD DISORDER; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REMISSION; REVIEW; SECONDARY AMENORRHEA; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VEIN THROMBOSIS; XEROSTOMIA; INDUCTION CHEMOTHERAPY; INFLAMMATORY BOWEL DISEASES; MAINTENANCE CHEMOTHERAPY;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; INFLAMMATORY BOWEL DISEASES; MAINTENANCE CHEMOTHERAPY; REMISSION INDUCTION; THALIDOMIDE;

EID: 84982791147     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000004239     Document Type: Review

References (52)

1. Sheskin J. Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther 1965;6:303-6.
2. Teo SK, Resztak KE, Scheffler MA, et al. Thalidomide in the treatment of leprosy. Microbes Infect 2002;4:1193-202.
3. Yang CS, Kim C, Antaya RJ. Review of thalidomide use in the pediatric population. J Am Acad Dermatol J Am Acad Dermatol 2015;72: 703-11.
4. Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009;2: CD007351.
5. Srinivasan R, Akobeng AK. Thalidomide and thalidomide analogues for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009;2: CD007350.
6. Yang C, Singh P, Singh H, et al. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1079-93.
7. http://prisma-statement. org/documents/PRISMA%202009%20checklist. pdf.
8. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Chichester:John Wiley & Sons; 2008.
9. Simon M, Pariente B, Lambert J, et al. Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease. Clin Gastroenterol Hepatol 2016;14:966-72.
10. Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 2013;310:2164-73.
11. Gerich ME, Yoon JL, Targan SR, et al. Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther 2015;41:429-37.
12. Luo HQ, Tan B, Lü H, et al. An analysis of adverse drug reactions of thalidomide in treatment of immune-related bowel diseases. Zhonghua Nei Ke Za Zhi 2013;52:726-9.
13. Lazzerini M, Martelossi S, Marchetti F, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther 2007;25: 419-27.
14. Plamondon S,Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther 2007;25:557-67.
15. Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: pilot randomised clinical trial. Inflamm Bowel Dis 2015;21:1739-49.
16. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999;117:1271-7.
17. Leung YK, Huang Y. Clinical efficacy and mechanism of action of thalidomide in pediatric patients with refractory Crohn's disease. Gastroenterology 2014;146:S-452.
18. Scribano ML, Cantoro L, Mangiarotti R, et al. Thalidomide in immunosuppressors and anti-TNF unresponsive Crohn's disease patients: efficacy and side effects. J Crohn's Colitis 2011;3:183.
19. Sabate JM, Villarejo J, Lemann M, et al. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002;16:1117-24.
20. Tang J, Gao X, Zhi M, et al. Intravenous cyclophosphamide combined with thalidomide has a promising effect in refractory Crohn's disease. J Crohn's Colitis 2014;8:S247-8.
21. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-87.
22. Felipez LM, Gokhale R, Tierney MP, et al. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr 2012;54: 28-33.
23. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002;17:135-9.
24. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200.
25. Macumber C, Wettstein AP, Vickers CR, et al. Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Gastroenterology 1999;116:A767.
26. Gupta P, Gokhale R, Andrew H, et al. Thalidomide for refractory Crohn's disease failing infliximab. J Pediatr Gastroenterol Nutr 2003; 37:338-42.
27. Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of antitumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009;104:2973-86.
28. Scribano M, Monterubbianesi R, Cantoro L, et al. Association of thalidomide with anti-TNF-a therapy in Crohn's disease patients who lost response to anti-TNF-a: A case series. Dig Liver Dis 2014;46(suppl 2):S27.
29. Kam LY, Vasiliauskas EA, Abreu MT, et al. Open labeled pilot study of thalidomide(thal) as a novel therapy for medically resistant ulcerative colitis (UC). Gastroenterology 2000;118:A582.
30. Srinivasan R, Casson D. Thalidomide treatment for maintainance of infliximab induced response in refractory paediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2007;44:110.
31. AhmedM, El-Hadi S, Jenkins HR. Thalidomide in Crohn disease and the risk of peripheral neuropathy. J Pediatr Gastroenterol Nutr 2003;37:522.
32. Trebble T, Johns T, Duncan HD, et al. An open trial of thalidomide in refractory Crohn's colitis. Gut 2001;48:A89-90.
33. Zheng CF, Xu JH, Huang Y, et al. Treatment of pediatric refractory Crohn's disease with thalidomide. World J Gastroenterol 2011;17: 1286-91.
34. Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:576-85.
35. Lazzerini M, Martelossi S, Cont G, et al. Orofacial granulomatosis in children: think about Crohn's disease. Dig Liver Dis 2015;47:338-41.
36. Kane S, Stone LJ, Ehrenpreis E. Thalidomide as salvage therapy for patients with delayed hypersensitivity response to infliximab: a case series. J Clin Gastroenterol 2002;35:149-50.
37. Cohen LB. Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004;18:101-4. 419.
38. Bauditz J, Schachschal G, Wedel S, et al. Thalidomide for treatment of severe intestinal bleeding. Gut 2004;53:609-12.
39. Fleming FJ, Vytopil M, Chaitow J, et al. Thalidomide neuropathy in childhood. Neuromuscul Disord 2005;15:172-6.
40. Simon M, Gornet JM, Plane C, et al. Long term efficacy and toxicity of thalidomide in Crohn's disease. Gastroenterology 2004;126:A629.
41. Qian J, Li Y. Efficacy and safety of thalidomide in Chinese patients with refractory Crohn's disease. Gastroenterology 2013;144:S435-1435.
42. Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 2001;32: 178-81.
43. Scribano ML, Cantoro L, Marrollo M, et al. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-a drugs: report of 3 cases and literature review. J Clin Gastroenterol 2014;48:530-3.
44. Lazzerini M, Bramuzzo M, Martelossi S, et al. Amenorrhea in women treated with thalidomide: report of two cases and literature review. Inflamm Bowel Dis 2013;19:E10-1.
45. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003;1:194-205.
46. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology 2002;59:1872-5.
47. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004;62:2291-3.
48. Bastuji-Garin S, Ochonisky S, Bouche P, et al. Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002;119:1020-6.
49. Priolo T, Lamba LD, Giribaldi G, et al. Childhood thalidomide neuropathy: a clinical and neurophysiologic study. Pediatr Neurol 2008;38:196-9.
50. Carrier M, Le Gal G, Tay J, et al. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 2011;9:653-63.
51. Lazzerini M, Bramuzzo M, Maschio M, et al. Thromboembolism in pediatric inflammatory bowel disease: systematic review. Inflamm Bowel Dis 2011;17:2174-83.
52. Mansfield JC, Parkes M, Hawthorne AB, et al. A randomized, doubleblind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther 2007;26:421-30.